王麟，研究员，博导，国自然青年基金B类（“国家优青”）获得者

地址：北京市海淀区学院路38号病理楼326

邮箱：lin_wang@pku.edu.cn

2022年入职北京大学基础医学院病原生物学系。入职以来以通讯作者（含共同）在Gastroenterology、Gut、PNAS、Nat Commun、Hepatology、PLOS Pathogens和JVI期刊发表研究论文。作为编委参编国际首部HEV英文专著《Hepatitis E Virus》。主持国自然青年基金B类（“国家优青”），中国科协青年托举工程，北京“高创人才”计划，国家重点研发计划课题和国家自然科学基金面上项目等。现任中华预防医学会感染性疾病防控分会委员、中国微生物学会病毒学专业委员会青委、中华医学会医学病毒学分会青年学组成员。

研究方向：

1.人兽共患病毒跨种传播机制研究；

2.重要人类病毒感染模型建立与应用；

3.重要人类病毒致病机制研究。

学术任职：

PLOS Pathogens Editorial Board（编委）, Academic Editor；

hLife青年编委；

Journal of Clinical and Translational Hepatology青年编委；

《中华肝脏病杂志》青年编委；

研究成果（加粗为本人；#共同一作；*通讯作者）：

2026

1) Liu F#, Liu T#, Wu X#, Yu Z, Tong J, Wang L, Zhao C, Nie J, Wang Y, Wang K, Bai L, Xia P, Wang K, Wei G, Zheng ZZ, Wu D*, Huang W*, Wang Lin*. iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain pangenotype hepatitis E virus propagation. Gut. 2026;75(4):787-800.

2) Hu J#, Liu T#, Klöhn M#, Freistaedter A, Toprak E, Chi H, Gömer A, Pottkaemper L, Jordan P, Yang X, Zhang H, Becker J, Nkongolo S, Lohmann V, Steinmann E*, Wang Lin*, Dao Thi VL*. Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models. Gut. 2026:gutjnl-2025-336714. doi: 10.1136/gutjnl-2025-336714.

3) Zhang H#, Wu Y#, Wang H#, Liu T#, Liu X#, Chen J, Sun Y, Xue L, Li C, Liu H, Chen H, Qi Y, An T, Wang L, Jin Z, Yu C, Yang X, Li Y, Li H*, Xia C*, Yin X*, Wang Lin*. Experimental hepatitis E virus genotype 1 infection in three types of wild rodents. PLoS Pathog. 2026;22(3):e1014050.

4) Ju X#, Dong L#, Liu T#, Zhang F#, Sun X, Schwoerer MP, Ren W, Gong M, Ploss A, Qin W, Wu X*, Wang Lin*, Ding Q*. EIF4H and YBX1 are essential host factors for hepatitis E virus replication and pathogenesis. PNAS. 2026;123(10):e2529289123.

2025

1) Liu T#, Li J#, Yin X, Lu F, Zhao H, Wang Lin*, Qin CF*. Establishment of enterically transmitted hepatitis virus animal models using lipid nanoparticle-based full-length viral genome RNA delivery system. Gut. 2025;74(3):467-476. (Featured Video)

2) Liu X#, Liu T#, Shao Z, Xiong X, Qi S, Guan J, Wang M, Tang YD, Feng Z, Wang Lin*, Yin X*. Palmitoylation-dependent association with Annexin II directs hepatitis E virus ORF3 sorting into vesicles and quasi-enveloped virions. PNAS. 2025;122(1):e2418751122.

3) Chen Z#, Wang L#, Zhang Y#, Li G#, Yin J, Fan J, Liu T, Wu H, Huang Y, Huang W, Liu D, Zheng X, Zang X, Huang X, Song L, Wen S, Li J, Ying D, Fang M, Wang Y, Wu T, Sridhar S, Zhang J, Xia N*, Wang Lin*, Lu Y*, Zheng Z*. Substantial spillover burden of rat hepatitis E virus in humans. Nat Commun. 2025;16(1):4038.

2024

1) Liu T, He Q, Yang X, Li Y, Yuan D, Lu Q, Tang T, Guan G, Zheng L, Zhang H, Xia C, Yin X, Wei G, Chen X, Lu F, Wang Lin*. An Immunocompetent Mongolian Gerbil Model for Hepatitis E Virus Genotype 1 Infection. Gastroenterology. 2024;167(4):750-763.e10. (ESI高被引，With Editorials)

2) He Q, Liu T, Yang X, Yuan D, Lu Q, Li Y, Zhang H, Liu X, Xia C, Sridhar S, Tian L, Liu X, Meng L, Ning J, Lu F, Wang L, Yin X, Wang Lin*. Optimization of immunosuppression strategies for the establishment of chronic hepatitis E virus infection in rabbits. J Virol. 2024;98(7):e0084624.

2023

1) Ying D#, He Q#, Tian W#, Chen Y#, Zhang X, Wang S, Liu C, Chen Z, Liu Y, Fu L, Yan L, Wang L, Tang Z*, Wang Lin*, Zheng Z*, Xia N*. Urine is a viral antigen reservoir in hepatitis E virus infection. Hepatology. 2023;77(5):1722-1734. doi:10.1002/hep.32745. (With Editorials)

2022

1) He Q, Zhang F, Shu J, Li S, Liang Z, Du M, Liu X, Liu T, Li M, Yin X, Pan Q, Lu F*, Wang L*, Wang Lin*. Immunocompromised rabbit model of chronic HEV reveals liver fibrosis and distinct efficacy of different vaccination strategies. Hepatology. 2022;76(3):788-802. doi:10.1002/hep.32455. (Featured Article)

2) Li Y, Yu P, Kessler AL, Shu J, Liu X, Liang Z, Liu J, Li Y, Li P, Wang L, Wang Y, Ma Z, Liu A, Wang L, Bruno MJ, de Man RA, Peppelenbosch MP, Buschow SI, Wang Lin*, Wang Y*, Pan Q*. Hepatitis E virus infection activates NOD-like receptor family pyrin domain-containing 3 inflammasome antagonizing interferon response but therapeutically targetable. Hepatology. 2022;75(1):196-212.